• Explore /
  • Poster
  • / Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.

Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.

Abstract Poster

Authors

null

David Kersting

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany

David Kersting , Moon-Sung Kim , Lukas Puellen , Kathi Seidl-Rathkopf , Nicole Schinwald , Philani Mpofu , Ivy Altomare , Arun Sujenthiran , Trevor Joseph Royce , Christoph Buhl , Viktor Grünwald , Ken Herrmann , Jens Kleesiek , Boris A. Hadaschik

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 143)

DOI

10.1200/JCO.2024.42.4_suppl.143

Abstract #

143

Poster Bd #

F14

Abstract Disclosures

Similar Posters

First Author: Colin P Bergstrom

Poster

2024 ASCO Genitourinary Cancers Symposium

Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).

Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Frederic Pouliot

First Author: Ridvan Arda Demirci

First Author: Ken Herrmann